Overview

Study 212669: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema

Status:
Recruiting
Trial end date:
2021-12-10
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, single arm, 28-day treatment in participants with DME. The study will be composed of 3 periods for all participants: Screening, 28-day Treatment period, and Follow-up visit (approximately 28 days after the final dose).
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline